William Blair Estimates AbbVie's Q1 Earnings (NYSE:ABBV)

Key Points

• William Blair has raised its Q1 2026 earnings estimate for AbbVie to $3.11 per share, with expectations for full-year earnings in 2026 set at $14.52 EPS.
• Despite reporting earnings of $2.97 EPS for the last quarter, AbbVie missed analyst expectations of $3.24, though revenue increased by 6.6% year-over-year to $15.42 billion.
• AbbVie announced a quarterly dividend of $1.64 per share, representing a yield of 3.4%, with a payout ratio currently at 312.38%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Equities research analysts at William Blair raised their Q1 2026 earnings estimates for shares of AbbVie in a report issued on Thursday, July 31st. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of $3.11 for the quarter, up from their prior estimate of $3.00. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. William Blair also issued estimates for AbbVie's Q2 2026 earnings at $3.93 EPS, Q3 2026 earnings at $3.74 EPS, Q4 2026 earnings at $3.75 EPS and FY2026 earnings at $14.52 EPS.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The company had revenue of $15.42 billion for the quarter, compared to analysts' expectations of $14.93 billion. AbbVie had a return on equity of 518.10% and a net margin of 6.45%. The business's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.65 EPS.

Other equities analysts have also recently issued research reports about the stock. Morgan Stanley increased their price objective on shares of AbbVie from $250.00 to $255.00 and gave the stock an "overweight" rating in a research report on Friday. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $194.00 price objective on shares of AbbVie in a research report on Tuesday, April 8th. Raymond James Financial increased their target price on shares of AbbVie from $227.00 to $236.00 and gave the stock an "outperform" rating in a report on Friday. Guggenheim increased their target price on shares of AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a report on Friday. Finally, Bank of America increased their target price on shares of AbbVie to $204.00 and gave the stock a "hold" rating in a report on Monday, June 9th. Eight investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $212.81.

AbbVie Stock Performance

NYSE:ABBV opened at $195.17 on Monday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. The stock has a market capitalization of $344.75 billion, a P/E ratio of 92.94, a PEG ratio of 1.27 and a beta of 0.50. The company has a 50 day moving average price of $188.33 and a 200 day moving average price of $190.42. AbbVie has a fifty-two week low of $163.81 and a fifty-two week high of $218.66.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.4%. The ex-dividend date is Tuesday, July 15th. AbbVie's dividend payout ratio (DPR) is currently 312.38%.

Institutional Investors Weigh In On AbbVie

Several hedge funds and other institutional investors have recently bought and sold shares of ABBV. Marshall & Sullivan Inc. WA purchased a new position in AbbVie during the 2nd quarter worth $25,000. TD Capital Management LLC grew its position in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock worth $27,000 after purchasing an additional 58 shares during the last quarter. EnRich Financial Partners LLC grew its position in AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after purchasing an additional 110 shares during the last quarter. Abound Financial LLC purchased a new position in AbbVie during the 1st quarter worth $30,000. Finally, Siemens Fonds Invest GmbH grew its position in AbbVie by 197.6% during the 4th quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock worth $32,000 after purchasing an additional 119,141 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.